U.S. drug producer Pfizer has signed a contract with Germany’s BioNTech SE to co-find a potential vaccine for the coronavirus using BioNTech’s mRNA-based drug development platform.
The drug producers will start the partnership immediately and have signed a letter of intent for the vaccine’s distribution outside China, they asserted in a joint statement.
The companies stated they will conclude financial terms, and details regarding development, manufacturing and potential commercialization of the vaccine over the following few weeks.
On Sunday, the German authorities were trying to cease the U.S. from persuading CureVac, another German drug producer working on an experimental vaccine for the coronavirus, to move its research to the U.S.
Pfizer and BioNTech will use research and development facilities from each company, including in the U.S. and Germany, the companies stated.
BioNTech Monday reached a collaboration contract with Shanghai Fosun Pharmaceutical over its rights in China to its experimental coronavirus vaccine, aiming to begin testing on humans from late April.
The competition is on to develop an immunization, which is seen as thus far the most effective tool to halt the global spread of the virus.
Competitor Moderna, which is working with the U.S. National Institutes of Health, on Monday, declared that it dosed the first patient with its experimental coronavirus vaccine in an early-stage trial.
Pfizer pairs up with BioNTech to develop mRNA-based vaccines for influenza.